Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Toyobo Co. Ltd.
WARNING LETTER
•Toyobo Co. Ltd.•February 25, 2021

Toyobo Co. Ltd. – FDA Warning Letter, Feb 25, 2021

Record Details

The FDA inspected Toyobo Co. Ltd. in Shiga, Japan, from February 15-25, 2021, identifying significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210 and 211, rendering their drug products adulterated. The firm failed to thoroughly investigate unexplained discrepancies or failures of batches to meet specifications (21 CFR 211.192). Specifically, they inadequately investigated recurring extrinsic particulate contamination in sterile drug products, failing to determine root causes and implement timely corrective actions. Furthermore, the firm's investigation into reported data integrity breaches was insufficient to determine the full scope of problems. These breaches included operators failing to consistently perform personnel and environmental monitoring, wiping equipment before sampling, misreporting nonviable particle data, and repeating monitoring instead of reporting high values. These issues compromised the sterility assurance of drug products and indicated a systemic failure in data integrity, involving multiple operators. The FDA requires a comprehensive, independent assessment of their investigation system, updated risk assessments for marketed batches, a review of defect limits, and a detailed remediation plan for contamination hazards. The firm must also provide a plan for appropriate aseptic practices, supervisory oversight, and a comprehensive assessment of their Quality Unit's authority and resources. A thorough investigation into data inaccuracies, a risk assessment of their effects on drug quality, and a global CAPA plan are also mandated. The FDA strongly recommends engaging a qualified CGMP consultant. Failure to address these violations may result in import alerts and impact future drug approvals.

Company
Toyobo Co. Ltd.
Inspection date
February 25, 2021
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 93bb6541-a2a7-490b-addf-4c3c51348f17

Violation Codes8
21 CFR 21021 CFR 21121 CFR 211.192FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(b)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Toyobo Co. Ltd.
  • 483 - 2023-02-22February 22, 2023
  • 483 - 2021-02-25February 25, 2021
  • 483 - 2019-07-30July 30, 2019
  • 483 - 2018-01-15January 15, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Toyobo Co. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.